In summary, [225Ac]Ac-PSMA RLT holds substantial promise as a transformative therapy in advanced prostate cancer, with demonstrated activity in difficult-to-treat populations and emerging applications in earlier lines of care. This evidence concerns the gene FOLH1 and prostate carcinoma.